Patents by Inventor Nicholas Mitsiades
Nicholas Mitsiades has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230167101Abstract: Embodiments of the present disclosure pertain to compositions that include a compound that inhibits the histone acetyl transferase activity of a protein, such as p300 and/or CBP. Further embodiments of the present disclosure pertain to methods of inhibiting the histone acetyl transferase activity of a protein by exposing the protein to a composition that contains one or more of the compounds of the present disclosure. The compositions of the present disclosure may be exposed to a protein in vitro or in vivo. Additional embodiments of the present disclosure pertain to methods of treating a cancer in a subject by administering a composition of the present disclosure to the subject in order to treat the cancer.Type: ApplicationFiled: April 8, 2021Publication date: June 1, 2023Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Yongcheng Song, Fangrui Wu, Shenyou Nie, Yuanda Hua, Yi-Lun Lin, Salma Kaochar, Nicholas Mitsiades
-
Patent number: 10227656Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.Type: GrantFiled: November 7, 2014Date of Patent: March 12, 2019Assignee: Baylor College of MedicineInventors: Bin He, Rainer B. Lanz, Nicholas Mitsiades, Qin Feng
-
Publication number: 20190011433Abstract: The invention provides a cell co-culture for the selective evaluation of the response of a cell of interest in the co-culture, and methods of using the co-culture. The cell co-culture and the methods are suitable for large-scale/high throughput screening for compounds useful for affecting at least one biological function or event of at least one cell type in the co-culture. The invention further provides kits for using the screening assays.Type: ApplicationFiled: February 5, 2018Publication date: January 10, 2019Inventors: Constantine S. Mitsiades, Douglas W. McMillin, Joseph M. Negri, Nicholas Mitsiades, Kenneth C. Anderson
-
Patent number: 10082510Abstract: Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.Type: GrantFiled: May 5, 2015Date of Patent: September 25, 2018Assignee: Baylor College of MedicineInventors: Bert W. O'Malley, Subhamoy Dasgupta, Nicholas Mitsiades, Arun Sreekumar, Sean E. Mcguire
-
Publication number: 20170067903Abstract: Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.Type: ApplicationFiled: May 5, 2015Publication date: March 9, 2017Applicant: Baylor College of MedicineInventors: Bert W. O'Malley, Subhamoy Dasgupta, Nicholas Mitsiades, Arun Sreekumar, Sean E. Mcguire
-
Publication number: 20160281170Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRDl. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRDl is overexpressed.Type: ApplicationFiled: November 7, 2014Publication date: September 29, 2016Inventors: Bin He, Rainer B. Lanz, Nicholas Mitsiades, Qin Feng
-
Patent number: 8685954Abstract: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.Type: GrantFiled: September 23, 2011Date of Patent: April 1, 2014Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Kenneth C. Anderson, Teru Hideshima, Constantine S. Mitsiades, Nicholas Mitsiades
-
Publication number: 20130274142Abstract: The invention provides a cell co-culture for the selective evaluation of the response of a cell of interest in the co-culture, and methods of using the co-culture. The cell co-culture and the methods are suitable for large-scale/high throughput screening for compounds useful for affecting at least one biological function or event of at least one cell type in the co-culture. The invention further provides kits for using the screening assays.Type: ApplicationFiled: March 13, 2013Publication date: October 17, 2013Inventors: Constantine S. Mitsiades, Douglas W. McMillin, Joseph M. Negri, Nicholas Mitsiades, Kenneth C. Anderson
-
Patent number: 8466147Abstract: Herein is provided methods and compositions for treating cancer. In one embodiment, a method is provided for treating a patient suffering from cancer, the method comprising administering to the patient an effective amount of reversine, reversine analog or reversine containing agent. In another embodiment, compositions comprising reversine are provided. Such compositions may further comprise additional active agents and other additives. The compositions and methods provided herein are useful, for example, in the area of medicine.Type: GrantFiled: November 12, 2007Date of Patent: June 18, 2013Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Kenneth C. Anderson, Nicholas Mitsiades, Joseph Negri, Douglas W. McMillin, Constantine S. Mitsiades
-
Publication number: 20120214757Abstract: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.Type: ApplicationFiled: September 23, 2011Publication date: August 23, 2012Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Kenneth C. Anderson, Teru Hideshima, Constantine S. Mitsiades, Nicholas Mitsiades
-
Patent number: 8026230Abstract: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.Type: GrantFiled: April 29, 2005Date of Patent: September 27, 2011Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Kenneth C. Anderson, Teru Hideshima, Constantine S. Mitsiades, Nicholas Mitsiades
-
Publication number: 20100255999Abstract: The invention provides a cell co-culture for the selective evaluation of the response of a cell of interest in the co-culture, and methods of using the co-culture. The cell co-culture and the methods are suitable for large-scale/high throughput screening for compounds useful for affecting at least one biological function or event of at least one cell type in the co-culture. The invention further provides kits for using the screening assays.Type: ApplicationFiled: February 1, 2008Publication date: October 7, 2010Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Constantine S. Mitsiades, Douglas W. McMillin, Joseph M. Negri, Nicholas Mitsiades, Kenneth C. Anderson
-
Publication number: 20100172893Abstract: Herein is provided methods and compositions for treating cancer. In one embodiment, a method is provided for treating a patient suffering from cancer, the method comprising administering to the patient an effective amount of reversine, reversine analog or reversine containing agent. In another embodiment, compositions comprising reversine are provided. Such compositions may further comprise additional active agents and other additives. The compositions and methods provided herein are useful, for example, in the area of medicine.Type: ApplicationFiled: November 12, 2007Publication date: July 8, 2010Inventors: Kenneth C. Anderson, Nicholas Mitsiades, Joseph Negri, Douglas W. McMillin, Constantine S. Siades
-
Publication number: 20080193462Abstract: The invention methods using a insulin-like growth factor receptor inhibitor to inhibit tumor cell growth in a subject in need thereof.Type: ApplicationFiled: February 25, 2005Publication date: August 14, 2008Inventors: Andrew Kung, Constantine S. Mitsiades, Nicholas Mitsiades
-
Patent number: 7381703Abstract: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.Type: GrantFiled: March 12, 2004Date of Patent: June 3, 2008Assignees: Dana-Faber Cancer Institute, Inc., Pharma Mar, S.A.Inventors: Joseph R. Bertino, Daniel Medina, Glynn Thomas Faircloth, Constantine S. Mitsiades, Kenneth Anderson, Nicholas Mitsiades
-
Publication number: 20070149445Abstract: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.Type: ApplicationFiled: March 12, 2004Publication date: June 28, 2007Inventors: Joseph Bertino, Daniel Medina, Glynn Faircloth, Constantine Mitsiades, Kenneth Anderson, Nicholas Mitsiades
-
Publication number: 20060172926Abstract: Aplidine and aplidine analogues are used in the manufacture of a medicament for treating multiple myeloma.Type: ApplicationFiled: March 12, 2004Publication date: August 3, 2006Inventors: Joseph Bertino, Daniel Medina, Glynn Faircloth, Constantine Mitsiades, Kenneth Anderson, Nicholas Mitsiades
-
Publication number: 20050267037Abstract: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.Type: ApplicationFiled: April 29, 2005Publication date: December 1, 2005Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Kenneth Anderson, Teru Hideshima, Constantine Mitsiades, Nicholas Mitsiades